 Pharmaceutical Preparations
"Pharmaceutical Preparations" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.
| Descriptor ID |
D004364
|
| MeSH Number(s) |
D26
|
| Concept/Terms |
Pharmaceutical Preparations- Pharmaceutical Preparations
- Preparations, Pharmaceutical
- Pharmaceutical Products
- Products, Pharmaceutical
- Drugs
- Pharmaceutic Preparations
- Preparations, Pharmaceutic
|
Below are MeSH descriptors whose meaning is more general than "Pharmaceutical Preparations".
Below are MeSH descriptors whose meaning is more specific than "Pharmaceutical Preparations".
This graph shows the total number of publications written about "Pharmaceutical Preparations" by people in UAMS Profiles by year, and whether "Pharmaceutical Preparations" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2021 | 4 | 2 | 6 | | 2020 | 6 | 1 | 7 | | 2019 | 2 | 0 | 2 | | 2018 | 1 | 2 | 3 | | 2017 | 2 | 0 | 2 | | 2016 | 2 | 1 | 3 | | 2015 | 2 | 2 | 4 | | 2014 | 1 | 0 | 1 | | 2013 | 4 | 2 | 6 | | 2012 | 1 | 2 | 3 | | 2011 | 2 | 2 | 4 | | 2010 | 2 | 1 | 3 | | 2008 | 3 | 2 | 5 | | 2007 | 1 | 0 | 1 | | 2006 | 3 | 0 | 3 | | 2005 | 1 | 0 | 1 | | 2003 | 4 | 1 | 5 | | 2000 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 1996 | 0 | 3 | 3 | | 1995 | 0 | 1 | 1 | | 1993 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pharmaceutical Preparations" by people in Profiles over the past ten years.
-
Karamchandani DM, Hammad H, Chetty R, Arnold CA. New Kids on the Block. Arch Pathol Lab Med. 2021 12 01; 145(12):1569-1584.
-
Samanta D, Elumalai V, Desai VC, Hoyt ML. Conceptualization and implementation of an interdisciplinary clinic for children with drug-resistant epilepsy during the COVID-19 pandemic. Epilepsy Behav. 2021 12; 125:108403.
-
Fullerton MS, Colonne PM, Dragan AL, Brann KR, Kurten RC, Voth DE. Neurotransmitter System-Targeting Drugs Antagonize Growth of the Q Fever Agent, Coxiella burnetii, in Human Cells. mSphere. 2021 08 25; 6(4):e0044221.
-
Xie H, Guarino H, Moore SK, Acosta M, Budney AJ, Rosenblum A, Marsch LA, Fong C. Web-based cognitive behavior therapy for chronic pain patients with aberrant drug-related behavior: How did it work and for whom? J Behav Med. 2021 10; 44(5):704-714.
-
Gonzalez-Jimenez A, Suzuki A, Chen M, Ashby K, Alvarez-Alvarez I, Andrade RJ, Lucena MI. Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machine learning approach. Arch Toxicol. 2021 05; 95(5):1793-1803.
-
Chorley BN, Ellinger-Ziegelbauer H, Tackett M, Simutis FJ, Harrill AH, McDuffie J, Atabakhsh E, Nassirpour R, Whiteley LO, Léonard JF, Carswell GK, Harpur E, Chen CL, Gautier JC. Urinary miRNA Biomarkers of Drug-Induced Kidney Injury and Their Site Specificity Within the Nephron. Toxicol Sci. 2021 02 26; 180(1):1-16.
-
Kilic ID, Cilingiroglu M. Drug-eluting stent, drug eluting balloon controversy in peripheral artery disease; what is the verdict? Catheter Cardiovasc Interv. 2020 11; 96(6):1315-1316.
-
Grossman SA, Romo CG, Rudek MA, Supko J, Fisher J, Nabors LB, Wen PY, Peereboom DM, Ellingson BM, Elmquist W, Barker FG, Kamson D, Sarkaria JN, Timmer W, Bindra RS, Ye X. Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery. Neuro Oncol. 2020 10 14; 22(10):1422-1424.
-
Thrailkill KM, Bunn RC, Uppuganti S, Ray P, Popescu I, Kalaitzoglou E, Fowlkes JL, Nyman JS. Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits. Bone. 2020 12; 141:115625.
-
Meteliuk A, Prokhorova T, Filippovych S, Ompad DC, Zaller N. The role of access to integrated services at opioid agonist treatment sites in reaching 90-90-90 cascade in people who inject drugs in Ukraine: Country-level data. Drug Alcohol Depend. 2020 11 01; 216:108216.
-
Chichester K, Drawve G, Sisson M, McCleskey B, Dye DW, Cropsey K. Examining the neighborhood-level socioeconomic characteristics associated with fatal overdose by type of drug involved and overdose setting. Addict Behav. 2020 12; 111:106555.
-
Khojasteh SC, Driscoll JP, Jackson KD, Miller GP, Mitra K, Rietjens IMCM, Zhang D. Novel advances in biotransformation and bioactivation research-2019 year in review. Drug Metab Rev. 2020 08; 52(3):333-365.
-
Saunders EC, Moore SK, Walsh O, Metcalf SA, Budney AJ, Scherer E, Marsch LA. Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders. J Subst Abuse Treat. 2020 04; 111:54-66.
-
Barrio S, Munawar U, Zhu YX, Giesen N, Shi CX, Viá MD, Sanchez R, Bruins L, Demler T, Müller N, Haertle L, Garitano A, Steinbrunn T, Danhof S, Cuenca I, Barrio-Garcia C, Braggio E, Rosenwald A, Martinez-Lopez J, Rasche L, Raab MS, Stewart AK, Einsele H, Stühmer T, Kortüm KM. IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. Haematologica. 2020 05; 105(5):e237-e241.
-
Kennon-McGill S, Clemens MM, McGill MR. Expression of drug metabolizing enzymes and transporters in the cochlea: Implications for drug delivery and ototoxicity. Hear Res. 2019 08; 379:98-102.
-
van den Anker J, Reed MD, Allegaert K, Kearns GL. Developmental Changes in Pharmacokinetics and Pharmacodynamics. J Clin Pharmacol. 2018 10; 58 Suppl 10:S10-S25.
-
Khojasteh SC, Miller GP, Mitra K, Rietjens IMCM. Biotransformation and bioactivation reactions - 2017 literature highlights *. Drug Metab Rev. 2018 08; 50(3):221-255.
-
George N, Chen M, Yuen N, Hunt CM, Suzuki A. Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury. Regul Toxicol Pharmacol. 2018 Apr; 94:101-107.
-
Hirashima R, Itoh T, Tukey RH, Fujiwara R. Prediction of drug-induced liver injury using keratinocytes. J Appl Toxicol. 2017 07; 37(7):863-872.
-
Zharov VP, Latyshev AS. Laser Non-Contact Drug Delivery Methods: Mathematical and Experimental Substantiation. Crit Rev Biomed Eng. 2017; 45(1-6):303-317.
-
Jones SM, Chowdhury ZK, Watts MJ. A taxonomy of chemicals of emerging concern based on observed fate at water resource recovery facilities. Chemosphere. 2017 Mar; 170:153-160.
-
Hanna J, Bian J, Hogan WR. An accurate and precise representation of drug ingredients. J Biomed Semantics. 2016; 7:7.
-
Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today. 2016 Apr; 21(4):648-53.
-
Zhang J, Doshi U, Suzuki A, Chang CW, Borlak J, Li AP, Tong W. Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles. Chem Biol Interact. 2016 Aug 05; 255:3-11.
-
Nedosekin DA, Foster S, Nima ZA, Biris AS, Galanzha EI, Zharov VP. Photothermal confocal multicolor microscopy of nanoparticles and nanodrugs in live cells. Drug Metab Rev. 2015 08; 47(3):346-55.
-
Djoussé L, Petrone AB, Blackshear C, Griswold M, Harman JL, Clark CR, Talegawkar S, Hickson DA, Gaziano JM, Dubbert PM, Correa A, Tucker KL, Taylor HA. Prevalence and changes over time of ideal cardiovascular health metrics among African-Americans: the Jackson Heart Study. Prev Med. 2015 May; 74:111-6.
-
Bajcetic M, Kearns GL, Jovanovic I, Brajovic M, van den Anker JN. Availability of Oral Formulations Labeled for Use in Young Children in Serbia, Germany and the USA. Curr Pharm Des. 2015; 21(39):5668-73.
-
Abdel-Rahman SM, Ridge A, Kearns GL. Estimation of body weight in children in the absence of scales: a necessary measurement to insure accurate drug dosing. Arch Dis Child. 2014 Jun; 99(6):570-4.
-
James LP. Metabolomics: integration of a new "omics" with clinical pharmacology. Clin Pharmacol Ther. 2013 Nov; 94(5):547-51.
-
Jambhekar SS, Breen PJ. Drug dissolution: significance of physicochemical properties and physiological conditions. Drug Discov Today. 2013 Dec; 18(23-24):1173-84.
-
Kim J, Xi J, Si X, Berlinski A, Su WC. Hood nebulization: effects of head direction and breathing mode on particle inhalability and deposition in a 7-month-old infant model. J Aerosol Med Pulm Drug Deliv. 2014 Jun; 27(3):209-18.
-
Yang L, Price ET, Chang CW, Li Y, Huang Y, Guo LW, Guo Y, Kaput J, Shi L, Ning B. Gene expression variability in human hepatic drug metabolizing enzymes and transporters. PLoS One. 2013; 8(4):e60368.
-
Pogribny IP, Beland FA. Role of microRNAs in the regulation of drug metabolism and disposition genes in diabetes and liver disease. Expert Opin Drug Metab Toxicol. 2013 Jun; 9(6):713-24.
-
Kodell RL, Chen JJ. Quantitative benefit-risk analysis for evaluating drug therapies. J Biopharm Stat. 2013; 23(1):231-8.
-
Howell BA, Yang Y, Kumar R, Woodhead JL, Harrill AH, Clewell HJ, Andersen ME, Siler SQ, Watkins PB. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn. 2012 Oct; 39(5):527-41.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|